The Susan G. Komen Breast Cancer Foundation has awarded USD 15.4 million in breast cancer research grants to 35 researchers across 24 US institutions, with the funding cycle notable for its concentration on metastatic disease and precision medicine at a moment when federal research budgets face increasing pressure.
The grant portfolio directs 72% of funding toward metastatic breast cancer, which accounts for approximately 43,000 deaths annually in the US, and 88% toward precision medicine approaches. Research areas include AI-assisted diagnostics and treatment optimization, vaccine-based strategies targeting aggressive breast cancer subtypes, disease risk in younger populations, weight loss as a prevention strategy, and health equity initiatives. Awards span career stages, from Career Catalyst grants supporting early-career investigators to Leadership grants for established researchers at institutions including Dana-Farber Cancer Institute, Stanford University School of Medicine, Memorial Sloan Kettering Cancer Center, and Vanderbilt University Medical Center.
The announcement carries an explicit commentary on federal funding constraints. Victoria Wolodzko Smart, senior vice president of Mission at Komen, stated that demand for research support exceeds available government funding, creating particular barriers for early-career scientists. Komen positions itself as the largest nonprofit funder of breast cancer research outside the US government, with cumulative investment exceeding USD 1.1 billion since its founding — a benchmark that underscores the organization's structural role in sustaining research pipelines that federal mechanisms do not fully cover.